Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves both fluid secretion and abnormal proliferation of cyst-lining epithelial cells. The chloride channel of the cystic fibrosis transmembrane conductance regulator (CFTR) participates in secretion of cyst fluid, and the mammalian target of rapamycin (mTOR) pathway may drive proliferation of cyst epithelial cells. CFTR and mTOR are both negatively regulated by AMP-activated protein kinase (AMPK). Metformin, a drug in wide clinical use, is a pharmacological activator of AMPK. We find that metformin stimulates AMPK, resulting in inhibition of both CFTR and the mTOR pathways. Metformin induces significant arrest of cystic growth in both in vitro and ex vivo models of renal cystogenesis. In addition, metformin administration produces a significant decrease in the cystic index in two mouse models of ADPKD. Our results suggest a possible role for AMPK activation in slowing renal cystogenesis as well as the potential for therapeutic application of metformin in the context of ADPKD.
A utosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow and continuous development of cysts derived from renal tubular epithelial cells. The cysts profoundly alter renal architecture, compressing normal parenchyma and compromising renal function. Nearly half of ADPKD patients ultimately require renal replacement therapy. ADPKD is a common genetic disorder, affecting at least 1 in 1,000 individuals (1) . There currently are no effective specific clinical therapies for ADPKD.
Cystic growth and expansion in ADPKD are thought to result from both fluid secretion into cyst lumens and abnormal proliferation of the cyst-lining epithelium. The rate of fluid secretion into the cyst lumen is directly proportional to the amount of the cystic fibrosis transmembrane regulator (CFTR) chloride channel in the apical membranes of cyst-lining epithelial cells (2) . The evidence suggesting that CFTR acts as a significant contributor to cyst growth has inspired preclinical trials of CFTR inhibitors in cell and animal models of renal cystic disease (3, 4) .
The cells surrounding the cysts manifest increased proliferation (5, 6) . Mammalian target of rapamycin (mTOR) activity is elevated in models of polycystic kidney disease (PKD) and probably is responsible, at least in part, for this hyperproliferative phenotype (5) . mTOR is a serine/threonine kinase that regulates cell growth and proliferation as well as transcription and protein synthesis. Rapamycin inhibits mTOR's kinase activity (7, 8) . Indeed, treatment with rapamycin has been shown to improve parameters of renal cystic expansion in several animal models of ADPKD (5, 9) .
Interestingly, both the CFTR chloride channel and the mTOR signaling pathway are negatively regulated by the "energy-sensing" molecule, AMP-activated protein kinase (AMPK). AMPK phosphorylates and directly inhibits CFTR and indirectly antagonizes mTOR through phosphorylation of tuberous sclerosis protein 2 (TSC2) and Raptor (10) (11) (12) (13) . Both of these actions are consistent with the role of AMPK as a regulator that decreases energy-consuming processes such as transport, secretion, and growth when cellular ATP levels are low (14) . Thus, a drug that activates AMPK might inhibit both the secretory and the proliferative components of cyst expansion. Metformin, a drug in wide clinical use for both non-insulin-dependent diabetes mellitus (type 2 DM) and polycystic ovary syndrome, stimulates AMPK (15, 16) . We therefore examined whether metformin-induced activation of AMPK slows cystogenesis through inhibition of mTOR-mediated cellular proliferation and inhibition of CFTR-mediated fluid secretion.
Results
Metformin Stimulates AMPK and Phosphorylated Acetyl-CoA Carboxylase.
We first treated Madin-Darby canine kidney (MDCK) renal epithelial cells with metformin to evaluate AMPK activation. Activated AMPK is phosphorylated at residue Thr 172 of its α subunit. We performed Western blotting using a phosphospecific antibody to measure the level of the phosphorylated AMPK (pAMPK) (Fig. 1A) . We found that incubation with metformin for as little as 2 h significantly increases pAMPK levels (Fig. 1B) . To determine whether this effect was correlated with increased phosphorylation of an AMPK target, we evaluated metformin's effect on the AMPK-mediated inhibitory phosphorylation of acetylCoA carboxylase (ACC) (Fig. 1C) . Incubation of MDCK cells with metformin produced a significant increase in phosphorylated ACC (pACC) levels in 6 h (Fig. 1D) . In AMPK-α1 knockdown (AMPK-α1-KD) cells, metformin's effects on pAMPK and pACC levels are substantially blunted (Fig. S1 ). Treatment of mice with increasing doses of metformin administered daily for 3 d results in increasing levels of pAMPK throughout the nephron ( Fig. 1 E and F) .
Inhibition of CFTR-Dependent Short-Circuit Current by Metformin in MDCK Cells Is AMPK Dependent. We next examined the effect of metformin treatment on the CFTR chloride channel, which is inhibited by AMPK phosphorylation (17) (18) (19) . Because the CFTR drives, at least in part, the fluid secretion in PKD cystogenesis, we hypothesized that metformin-stimulated AMPK activity would inhibit CFTR channels in renal epithelial cells and slow the rate of cyst growth (20, 21) . To test whether metformin inhibits CFTR via AMPK in a kidney-derived epithelial cell line, CFTR was expressed by adenoviral transduction in three different polarized MDCK type II cell lines stably transfected with an empty vector or with shRNA plasmids directed against two isoforms of the catalytic α subunit of AMPK. MDCK cells endogenously express high concentrations of the α1 isoform of the AMPK catalytic α subunit and very low concentrations of the α2 isoform. Expression of the α1 shRNA construct reduced expression of this protein by ∼90%, whereas the α2 shRNA had no effect on α1 protein expression. Knockdown of α1 also reduced the level of total pAMPK by ∼90% ( Fig. 2A) . CFTR-dependent short-circuit current (I sc ) was measured for cells grown on filters mounted in Ussing chambers for 4 d following adenoviral transduction, with or without exposure to 1 mM metformin for 2-4 h before measurement. To initiate CFTRmediated secretion, CFTR-expressing and mock-transduced MDCK cells were treated with the cAMP agonists 3-isobutyl-1-methylxanthine (IBMX) and forskolin, and the experiment was concluded by the application of the specific CFTR inhibitor CFTR-Inh 172 (22) . Typical traces of I sc changes are shown in Fig. 2 B and C. CFTR-expressing cells generally showed an early peak in I sc , within 1-2 min following forskolin/IBMX treatment, followed by a lower plateau current within ∼5 min. This remaining current was sensitive to inhibition by CFTR-Inh 172 . Metformin (1 mM) pretreatment of empty vector-transfected and AMPK-α2-KD MDCK cells significantly reduced CFTR-dependent I sc by 60-70% relative to cells pretreated with vehicle (Fig. 2D) . However, there was no metformin-dependent inhibition of CFTR current in AMPK-α1-KD MDCK cells, suggesting that the metformin-induced inhibition of CFTR occurs specifically via an AMPK-α1-dependent mechanism.
Inhibition of mTOR by Metformin in MDCK Cells Is AMPK Dependent.
To determine whether metformin induces AMPK-mediated inhibition of mTOR activity, we tested whether mTOR activity is diminished in MDCK cells cultured in the presence of metformin by blotting for the phosphorylated form of the mTOR downstream target ribosomal S6 kinase (S6K) p70 subunit (p70 S6K) (Fig. 3A) relative to pan-S6K (Fig. 3B ). This inhibition is time dependent, with increasing exposure to metformin resulting in greater suppression of this pathway. Total S6K levels remain constant. The inhibition takes longer to achieve than inhibition of CFTR or ACC, consistent with the indirect inhibition of mTOR by AMPK via TSC2/1 and Rheb (Ras homolog enriched in brain) (Fig. 3C ). This effect is markedly less pronounced in AMPK-α1-KD cells (Fig. S1 ). To evaluate whether these changes in phospho-protein levels translated into changes in proliferation, an Alamar Blue assay was used to quantitate proliferation in wild-type and AMPK-α1-KD MDCK cells. In figure 3D , the y axis depicts cell number measured at each given concentration of metformin and normalized to the control value, which was obtained for the same cell type at the same time point without metformin treatment. Wildtype MDCK cells exhibited a metformin dose-dependent decrease in proliferation, but this response was diminished significantly in the AMPK-α1-KD MDCK cells (Fig. 3D) . At the highest concentration of metformin tested (5 mM), substantial growth suppression was detected in AMPK-KD cells, perhaps because of the low level of residual AMPK that is expressed in these KD cells ( Fig. 2A) or the effects of high doses of metformin on yet to be identified AMPK-independent pathways. A similar suppressive effect of metformin treatment on proliferation was observed in vivo. We performed immunofluorescence analyses on kidneys from metformin-treated and vehicle-treated cystic Pkd1 (Pkd1, polycystic kidney disease-1 gene; Ksp-Cre, kidney specific cadherin promoter-driven Cre recombinase) mice using an antibody directed against Ki67, a marker of actively proliferating cells (Fig.  S2) . In kidneys from vehicle-treated mice, 19.7 ± 3.8% of the cells exhibited Ki67 positivity (450 cells were counted from each of six mice) in comparison with 10.6 ± 3.6% of the cells in metformintreated mice (450 cells were counted from each of four mice) (P < 0.0074). To assess whether the effects of metformin treatment on proliferation correlate with the level of mTOR activity in the cystic kidneys before and after metformin treatment, we performed immunohistochemistry using an antibody directed against the activated form of an mTOR target. As depicted in Fig. S3 , we stained tissue from control and metformin-treated cystic mice with an antibody that detects the phosphorylated form of eukaryotic translation initiation factor 4E-binding protein 1 (p4E-BP1), an mTOR target whose level of phosphorylation commonly is used to report levels of mTOR activity (23). We find that the level of p4E-BP1 generally is higher in cyst-lining epithelial cells in control animals than in metformin-treated animals, an observation that is consistent with the interpretation that metformin treatment reduces the level of mTOR activation.
Metformin Treatment Slows Cystogenesis ex Vivo and in Vivo. The 2D culture models do not accurately depict cell growth in the 3D environment in which cysts develop. To evaluate metformin's effects in the context of cystogenesis, we suspended MDCK cells in a 3D collagen matrix and allowed them to form cysts spontaneously in the presence of forskolin and IBMX (24) . Cultures coincubated with metformin for the duration of cyst growth produced significantly smaller cysts than those similarly treated with forskolin or IBMX alone (P = 0.003, unpaired t test, n = 3 gels for each experimental condition) (Fig. 4A) . We next tested the effect of metformin on ex vivo cystogenesis. Kidneys were removed from C57/B6 mice at embryonic day 12.5 (E12.5). One embryonic kidney was cultured in the presence of membrane-permeable 8-bromo-cAMP (8-Br-cAMP) to stimulate fluid secretion, and the contralateral kidney was coincubated with 8-Br-cAMP and metformin for 4 d. Culture in the presence of 8-Br-cAMP induces cyst formation in embryonic mouse kidneys (4). Metformin treatment significantly decreased the fractional cyst area (P = 0.04, unpaired t test; n = 4 for each experimental condition). On day 5, metformin was removed from the treated embryonic kidney, and cyst growth recommenced in the treated kidney, demonstrating that metformin treatment slowed cyst growth without affecting the viability of the tissue (Fig. 4B) . Metformin Treatment Slows Cystogenesis in the in Vivo models of PKD. We next tested whether metformin slows cyst growth in a murine model of PKD. Initially, we used the most aggressive viable murine model of PKD (Pkd1 flox/-;Ksp-Cre) in which there is progression of renal cystic disease within the first week of life and death between the second and third weeks of life (6) . We treated these mice with daily i.p. injections of metformin (300 mg·kg
) dissolved in a 5% (mass/vol) dextrose solution from postnatal day 4 (P4) until P6. This dose is known to activate AMPK (25) . Mice then were killed, and kidneys were harvested at P7. The vehicletreated Pkd1 flox/ ;Ksp-Cre kidneys (Fig. 5C) were profoundly cystic and greatly enlarged compared with the Pkd1 +/+ ;Ksp-Cre kidneys (Fig. 5A) . In contrast, cyst burden was significantly reduced in the kidneys from the metformin-treated Pkd1 flox/-;Ksp-Cre mice (Fig.  5B) . Because metformin can affect body weight, the kidney weight: body weight ratio was not used as an end point (26) . Instead, the effect of metformin on renal morphology was quantitated by evaluating the cystic index, which determines the fraction of a given section that corresponds to luminal area (including both tubule and cyst lumens). Untreated Pkd1 flox/-;Ksp-Cre kidneys had a cystic index of 71.4 ± 4.0%, whereas the cystic index of metformin-treated Pkd1 flox/-;Ksp-Cre kidneys was 51.8 ± 5.2%. (P = 0.029; unpaired t test; n = 4 control mice and n = 8 metformintreated mice). In wild-type kidneys, this evaluation calculates a cystic index of 10% resulting from tubular lumens. Notably, although the metformin-treated kidney is still cystic, it displays significantly more parenchyma than the vector-treated control. Although metformin might prevent further cyst growth, it is unlikely that treatment reduces the size of preexisting cysts.
We established an inducible model for Pkd1 inactivation using a conditional Pkd1 flox allele in combination with a tamoxifen-inducible Cre recombinase (pCX-CreER) (6, 27, 28) . Induction of Cre expression before P13 leads to rapidly progressive cystic disease in Pkd1 flox/flox animals (29) . In this system, it is possible to initiate metformin treatment before or during cyst development. Thus, this model might replicate more accurately the clinical scenario in which metformin therapy could commence early in the disease process and act to prevent or slow subsequent cyst development. We initiated metformin treatment (300 mg·kg
) at P7 and then injected tamoxifen i.p. at P9 or P10 to initiate disease induction. We continued daily metformin injections until P18, when the animal was killed and kidneys were harvested for histology and cystic index evaluation. Once again, metformin treatment resulted in a smaller fractional cyst burden than seen in vehicle-treated controls (31% vs. 43%; P = 0.041, unpaired t test; n = 6 vehicletreated mice, and n = 7 for metformin-treated mice), a decrease of nearly one-third in the cyst burden (Fig. 5 D and E) . Discussion AMPK activity can be targeted pharmacologically with metformin to reduce the growth of renal cysts. Metformin acts through AMPK to decrease epithelial fluid secretion by directly inhibiting CFTR and to decrease cellular proliferation by indirectly targeting mTOR. Metformin stimulates AMPK phosphorylation in cultured MDCK renal epithelial cells, and this phosphorylation correlates with increased AMPK activity, as evidenced by an increase in the level of the AMPK-mediated inhibitory phosphorylation of ACC. Metformin's inhibitory action on CFTRmediated chloride transport is AMPK dependent. Additionally, we show that metformin inhibition of mTOR translates into an AMPK-dependent inhibition of cell proliferation. Using both an in vitro model of MDCK cell cystogenesis and embryonic kidneys ex vivo, we demonstrate that metformin decreases cyst size and fractional cyst area. Finally, we illustrate the potential thera- peutic utility of metformin by testing it in two murine models of ADPKD, both of which are attributable to inactivation of the gene encoding polycystin-1. Metformin is taken by millions of Americans each year. It currently is approved by the Food and Drug Administration for the treatment of type 2 DM and, intriguingly, for polycystic ovary syndrome, a disease that has a name similar to that of polycystic kidney disease but whose pathogenesis is even less well understood. In fact, metformin often is considered first-line therapy for the treatment of type 2 DM because of its relatively small sideeffect profile. Recent literature suggests that metformin's activation of AMPK may be the result of its ability to prevent AMP breakdown, although the exact mechanisms of action of metformin in polycystic ovary syndrome or in type 2 DM remain largely unknown (30) . Recent reports also suggest that metformin may exert an antineoplastic effect. It has been reported that metformin acts in a dose-dependent manner to inhibit the proliferation of breast cancer cells, and that this effect can be blocked in the presence of siRNA directed against AMPK (31) . This inhibition also is associated with a decrease in mTOR activation, suggesting that metformin's antiproliferative effect is directed through the activation of AMPK and consequent inhibition of mTOR.
In transporting epithelial cells, AMPK not only modulates CFTR activity but also inhibits the epithelial sodium channel (ENaC) (32) (33) (34) . Although in the cystic kidney this effect conceivably could lead to decreased fluid absorption and therefore perhaps to increased accumulation of cyst fluid, the role of ENaC in cyst-lining epithelial cells is uncertain (35) . CFTR can inhibit ENaC channel function directly. Thus, inhibition of CFTR by AMPK could reduce such sodium channel inhibition (36, 37) . Taken together, the effects of AMPK activation on ENaC function in the context of renal cystic disease are bimodal and complex. The net effect of AMPK modulation in vivo, however, is likely to reduce luminal fluid accumulation (38) .
Numerous therapies for ADPKD, including vasopressin receptor inhibitors, calcium-sensing receptor inhibitors, CFTR inhibitors, cell-cycle inhibitors, and rapamycin, are in development or in clinical trials (4, 9, 39, 40) . Each of these strategies targets one of the key processes (proliferation and secretion) thought to be involved in the pathogenesis of PKD. By acting through AMPK, metformin may offer the significant advantage of blocking both processes (Fig. S4) . Moreover, metformin already is approved by the Food and Drug Administration and generally is well tolerated. The most serious, albeit rare, side effect of metformin is lactic acidosis and, because metformin is cleared by the kidney, chronic renal disease has been considered a potential predisposing factor for this complication. Ideally, however, metformin use could be initiated at an early stage in ADPKD progression, before the development of substantial cyst burden and compromise of renal function, thus allowing maximal preventive benefit and minimizing the potential for renal dysfunction to limit the safe use of the drug (41, 42) . Given the relatively late onset and slow progression of ADPKD, it is conceivable that, even if metformin were to have only modest effects in delaying or slowing cyst development, it might increase significantly the time to the development of end-stage renal disease and perhaps reduce the need for renal replacement therapy.
In this study, only one dose known to activate AMPK in vivo was tested. When considered on a simple milligram per kilogram body weight basis, this dose appears considerably higher than the current maximum dose prescribed for patients with diabetes or polycystic ovary syndrome. However, human-equivalent dose extrapolation is calculated more accurately based on body surface area than on weight. When this calculation is performed for a 60-kg adult, the dose used in our mouse studies extrapolates to a daily dose of ∼1,500 mg (43) , well within the range in which metformin is safely used in humans. We have not tested the efficacy of lower doses or of alternative dosing regimens in these mouse models. It is likely, however, based on the established pharmacokinetics of metformin, that single daily dosing is suboptimal, and thus we almost certainly did not observe the maximal suppressive effects that metformin potentially could exert on the severity of cyst growth (44) . Support for this contention derives from the data presented in Fig. 4C , because in the embryonic kidney model, cyst growth resumes rapidly shortly after removal of metformin from the culture medium. Thus, shortterm intermittent exposure to metformin may not be adequate to suppress cyst development optimally. It is quite possible that even lower doses administered more frequently might produce beneficial effects in the setting of polycystic kidney disease. It is important to note that our efforts to assess effects of metformin treatment on renal functional parameters such as serum concentrations of serum urea nitrogen and creatinine were inconclusive, in part because of interindividual variability. Further studies, perhaps using more slowly progressive disease models, will be required to reduce this variance and to assess the extent to which metformin treatment can protect or improve renal function in the setting of PKD. In addition, subsequent development of metformin for this clinical application will require pharmacokinetic and pharmacodynamic studies designed to identify an ideal dosing regimen that achieves maximal activation of renal tubular AMPK.
In conclusion, we find that metformin stimulates AMPK, resulting in inhibition of both CFTR and mTOR and thereby both epithelial secretion and proliferation. Our data suggest the possible utility of metformin as a therapy for ADPKD and that AMPK is a potential pharmacological target for ADPKD therapy. The large body of knowledge associated with metformin administration might facilitate the translation of these findings into clinical trials to test the proposition that metformin is a safe and promising approach that exploits AMPK activity to treat this challenging disease.
Methods
Western Blotting and Proliferation Assay. Cultured MDCK cells were lysed, and protein was extracted for Western blotting using standard protocols. For experiments involving AMPK activation in vivo, kidneys were snap-frozen in situ, and homogenates were prepared according to published protocol before Western blotting (45) . Details and antibodies used are given in SI Methods.
Generation of AMPK-KD Cell Lines. AMPK-KD cell lines were established by lentiviral infection. Further details and targeting sequences are given in SI Methods.
CFTR Short-Circuit Current Measurements in MDCK II Cells. MDCK cells expressing either empty vector or shRNA against one of two AMPK isotypes underwent adenoviral transduction to express GFP-tagged CFTR. I sc was assessed by Ussing chamber measurement after stimulation with forskolin and 3-isobutyl-1-methylxanthine and then CFTR-Inh 172 to determine the CFTR-dependent change in I sc . Cells were pretreated with vector or metformin as noted. Further details are given in SI Methods.
In Vitro Cystogenesis. MDCK cells were suspended in a collagen matrix as previously described by Grantham and coworkers (24) . Further details and quantitation method are given in SI Methods.
Ex Vivo Cystogenesis. Embryonic kidneys were microdissected from timed pregnant C57BL/6 mice at E12.5, cultured per standard protocol with the addition of 8-Br-cAMP to promote cyst formation, and treated with either metformin or vector (4, 46) . Further details are given in SI Methods.
Mouse Strains, Histology, and Cystic Index. All animal protocols were approved and conducted in accordance with Yale Animal Resources Center and Institutional Animal Care and Use Committee regulations. Pkd1 flox/flox and Ksp-Cre lines have been described previously (6, 47, 48) . From P4 until P6, experimental mice received either metformin (300 mg/kg body weight) dissolved in 5% (mass/vol) dextrose or 5% (mass/vol) dextrose alone through daily i.p. injections. These mice were killed at P7. The pCX-CreER transgenic line (kindly provided by Corinne Lobe, University of Toronto, Toronto) gives generalized Cre expression based on the pCAGGS chicken β-actin promoter construct. Cre recombinase translocation to the nucleus was induced by
